Abstract
Introduction: Diabetes, kidney disease, and cardiovascular disease have complex interactions and coexistences that significantly worsen a patient’s overall health. Previous research results have shown that SGLT2i hypoglycemic drugs can not only effectively control blood sugar in diabetic patients but also protect the kidneys and heart. This study further focuses on diabetic patients with kidney disease to explore the effectiveness of using SGLT2i hypoglycemic drugs in avoiding heart-related complications or death. Methods: This is a multicenter retrospective cohort study using the Taipei Medical University Clinical Research Database (TMUCRD) as the data source. This study selected patients who suffered from both type 2 diabetes and chronic kidney disease from 1 January 2008 to 31 December 2020, as the research team. Integrated or separate 4-point major adverse cardiovascular events (4P-MACE) and mortality were the outcomes of this study. The Kaplan-Meier curves method and Cox proportional hazard regression analysis were used to explore the association between each influencing factor and the outcome. Results: A total of 5,005 patients with type 2 diabetes and CKD were included in this study, of which 524 patients were stably treated with SGLT2i, 3,952 patients were treated with DPP4i, and 529 patients were treated with TZD. The results showed that the SGLT2i user group had a significantly lower risk of 4P-MACE compared with the SGLT2i nonuser group (hazard ratio [HR]: 0.68, 95% CI [0.49, 0.95], p = 0.024). The SGLT2i group had a significantly lower risk of cardiovascular mortality compared with the DPP4i and TZD groups (HR: 0.37, 95% CI [0.21, 0.65], p < 0.001; HR: 0.42, 95% CI [0.20, 0.90], p = 0.025). Conclusion: This study found that for patients with both diabetes and kidney disease, SGLT2i is a better option than other oral hypoglycemic medications because it can significantly avoid the occurrence of heart-related complications. The results of this study can be used as a reference for clinical medication selection practice.
References
1.
Ndumele
CE
, Neeland
IJ
, Tuttle
KR
, Chow
SL
, Mathew
RO
, Khan
SS
, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association
. Circulation
. 2023
;148
(20
):1636
–64
. 2.
Thomas
MC
, Cooper
ME
, Zimmet
P
. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
. Nat Rev Nephrol
. 2016
;12
:73
–81
. 3.
Papademetriou
V
, Lovato
L
, Doumas
M
, Nylen
E
, Mottl
A
, Cohen
RM
, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes
. Kidney Int
. 2015
;87
(3
):649
–59
. 4.
Bakris
GL
. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus
. Mayo Clin Proc
. 2011
;86
(5
):444
–56
. 5.
Bhatt
DL
, Szarek
M
, Pitt
B
, Cannon
CP
, Leiter
LA
, McGuire
DK
, et al. Sotagliflozin in patients with diabetes and chronic kidney disease
. N Engl J Med
. 2021
;384
(2
):129
–39
. 6.
Heerspink
HJL
, Stefánsson
BV
, Correa-Rotter
R
, Chertow
GM
, Greene
T
, Hou
FF
, et al. Dapagliflozin in patients with chronic kidney disease
. N Engl J Med
. 2020
;383
(15
):1436
–46
. 7.
The EMPA-KIDNEY Collaborative Group
, Herrington
WG
, Staplin
N
, Wanner
C
, Green
JB
, Hauske
SJ
, Emberson
JR
, et al. Empagliflozin in patients with chronic kidney disease
. N Engl J Med
. 2023
;388
(2
):117
–27
. 8.
Perkovic
V
, Jardine
MJ
, Neal
B
, Bompoint
S
, Heerspink
HJL
, Charytan
DM
, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
. N Engl J Med
. 2019
;380
(24
):2295
–306
. 9.
Cherney
DZI
, Ferrannini
E
, Umpierrez
GE
, Peters
AL
, Rosenstock
J
, Carroll
AK
, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
. Diabetes Obes Metab
. 2021
;23
(12
):2632
–42
. 10.
Yau
K
, Dharia
A
, Alrowiyti
I
, Cherney
DZI
. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations
. Kidney Int Rep
. 2022
;7
(11
):2546
–7
. 11.
Shrishrimal
K
, Hart
P
, Michota
F
. Managing diabetes in hemodialysis patients: observations and recommendations
. Cleve Clin J Med
. 2009
;76
(11
):649
–55
. 12.
Cherney
DZI
, Cooper
ME
, Tikkanen
I
, Pfarr
E
, Johansen
OE
, Woerle
HJ
, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
. Kidney Int
. 2018
;93
(1
):231
–44
. 13.
Cannon
CP
, Pratley
R
, Dagogo-Jack
S
, Mancuso
J
, Huyck
S
, Masiukiewicz
U
, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes
. N Engl J Med
. 2020
;383
(15
):1425
–35
. 14.
Neal
B
, Perkovic
V
, Mahaffey
KW
, de Zeeuw
D
, Fulcher
G
, Erondu
N
, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes
. N Engl J Med
. 2017
;377
(7
):644
–57
. 15.
Wiviott
SD
, Raz
I
, Bonaca
MP
, Mosenzon
O
, Kato
ET
, Cahn
A
, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes
. N Engl J Med
. 2019
;380
(4
):347
–57
. 16.
Zinman
B
, Wanner
C
, Lachin
JM
, Fitchett
D
, Bluhmki
E
, Hantel
S
, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
. N Engl J Med
. 2015
;373
(22
):2117
–28
. 17.
Nguyen
P-A
, Hsu
M-H
, Chang
T-H
, Yang
HC
, Huang
CW
, Liao
CT
, et al. Taipei Medical University Clinical Research Database: a collaborative hospital EHR database aligned with international common data standards
. BMJ Health Care Inform
. 2024
;31
(1
):e100890
. 18.
Kidney Disease Improving Global Outcomes KDIGO Diabetes Work Group
. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
. Kidney Int
. 2020
;98
(4S
):S1
–115
. 19.
Khera
R
, Schuemie
MJ
, Lu
Y
, Ostropolets
A
, Chen
R
, Hripcsak
G
, et al. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies
. BMJ Open
. 2022
;12
(6
):e057977
. 20.
Rosenstock
J
, Perkovic
V
, Johansen
OE
, Cooper
ME
, Kahn
SE
, Marx
N
, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial
. JAMA
. 2019
;321
(1
):69
–79
. 21.
Toyama
T
, Neuen
BL
, Jun
M
, Ohkuma
T
, Neal
B
, Jardine
MJ
, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
. Diabetes Obes Metab
. 2019
;21
(5
):1237
–50
. 22.
Lee
G
, Oh
SW
, Hwang
SS
, Yoon
JW
, Kang
S
, Joh
HK
, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: a network meta-analysis
. PLoS One
. 2017
;12
(5
):e0177646
. 23.
Zheng
SL
, Roddick
AJ
, Aghar-Jaffar
R
, Shun-Shin
MJ
, Francis
D
, Oliver
N
, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis
. JAMA
. 2018
;319
(15
):1580
–91
. 24.
Filion
KB
, Lix
LM
, Yu
OH
, Dell’Aniello
S
, Douros
A
, Shah
BR
, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
. BMJ
. 2020
;370
:m3342
. 25.
Xie
Y
, Bowe
B
, Gibson
AK
, McGill
JB
, Maddukuri
G
, Yan
Y
, et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases
. Diabetes Care
. 2020
;43
(11
):2859
–69
. 26.
Kohsaka
S
, Lam
CSP
, Kim
DJ
, Cavender
MA
, Norhammar
A
, Jørgensen
ME
, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
. Lancet Diabetes Endocrinol
. 2020
;8
(7
):606
–15
. 27.
Pasternak
B
, Wintzell
V
, Melbye
M
, Eliasson
B
, Svensson
AM
, Franzén
S
, et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: scandinavian cohort study
. BMJ
. 2020
;369
:m1186
. 28.
Patorno
E
, Goldfine
AB
, Schneeweiss
S
, Everett
BM
, Glynn
RJ
, Liu
J
, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
. BMJ
. 2018
;360
:k119
. 29.
Peng
ZY
, Yang
CT
, Kuo
S
, Wu
CH
, Lin
WH
, Ou
HT
. Restricted mean survival time analysis to estimate SGLT2i-associated heterogeneous treatment effects on primary and secondary prevention of cardiorenal outcomes in patients with type 2 diabetes in taiwan
. JAMA Netw Open
. 2022
;5
(12
):e2246928
. 30.
Persson
F
, Nyström
T
, Jørgensen
ME
, Carstensen
B
, Gulseth
HL
, Thuresson
M
, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study
. Diabetes Obes Metab
. 2018
;20
:344
–51
. 31.
Yang
CT
, Peng
ZY
, Chen
YC
, Ou
HT
, Kuo
S
. Cardiovascular benefits with favorable renal, amputation and hypoglycemic outcomes of SGLT-2 inhibitors in type 2 diabetes from the Asian perspective: a population-based cohort study and systematic review
. Front Endocrinol
. 2022
;13
:836365
. 32.
Yang
Q
, Lang
Y
, Yang
W
, Yang
F
, Yang
J
, Wu
Y
, et al. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials
. Diabetes Res Clin Pract
. 2023
;198
:110592
. 33.
Rhee
JJ
, Han
J
, Montez-Rath
ME
, Kim
SH
, Cullen
MR
, Stafford
RS
, et al. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease
. Diabetes Obes Metab
. 2022
;24
(5
):928
–37
. 34.
Shi
Q
, Nong
K
, Vandvik
PO
, Guyatt
GH
, Schnell
O
, Rydén
L
, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
. BMJ
. 2023
;381
:e074068
. 35.
Chan
GC
, Ng
JK
, Chow
KM
, Szeto
CC
. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: a population-based propensity score-matched cohort study
. Diabetes Res Clin Pract
. 2023
;195
:110200
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
